You are here: Home: PCU 2 | 2006: Case 4: Select publications

SELECT PUBLICATIONS

Armstrong AJ, Carducci MA. Chemotherapy for advanced prostate cancer: Results of new clinical trials and future studies. Curr Oncol Rep 2005;7(3):220-7. Abstract

Berry W, Eisenberger M. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy. Oncologist 2005;10(Suppl 3):30-9. Abstract

Berthold DR et al. Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol 2005;23(32):8247-52. Abstract

Bill-Axelson A et al; Scandinavian Prostate Cancer Group Study No. 4. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352(19):1977-84. Abstract

Chodak GW, Warren KS. Watchful waiting for prostate cancer: A review article. Prostate Cancer Prostatic Dis 2006;9(1):25-9. Abstract

Donohue KM, Petrylak DP. Chemotherapy agents and timing of chemotherapy in prostate cancer management. Curr Urol Rep 2005;6(3):224-7. Abstract

Gilbert DC, Parker C. Docetaxel for the treatment of prostate cancer. Future Oncol 2005;1(3):307-14. Abstract

Gleave M, Kelly WK. High-risk localized prostate cancer: A case for early chemotherapy. J Clin Oncol 2005;23(32):8186-91. Abstract

Hainsworth JD et al. Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate-specific antigen levels after primary treatment for prostate cancer: A Phase II trial of the Minnie Pearl Cancer Research Network. Clin Genitourin Cancer 2006;4(4):287-92. Abstract

Holmberg L et al; Scandinavian Prostatic Cancer Group Study Number 4. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347(11):781-9. Abstract

Kibel AS. An interdisciplinary approach to treating prostate cancer. Urology 2005;65(6 Suppl):13-8. Abstract

Kirby R. Management of clinically localized prostate cancer by radical prostatectomy followed by watchful waiting. Nat Clin Pract Urol 2005;2(6):298-303. Abstract

Klotz L. Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol 2006;24(1):46-50. Abstract

Klotz L. Active surveillance for prostate cancer: For whom? J Clin Oncol 2005;23(32):8165-9. Abstract

Michels J et al. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: Does sequence matter? Cancer 2006;106(5):1041-6. Abstract

Petrylak DP et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006;98(8):516-21. Abstract

Petrylak D. Therapeutic options in androgen-independent prostate cancer: Building on docetaxel. BJU Int 2005;96(Suppl 2):41-6. Abstract

Petrylak DP et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513-20. Abstract

Pienta KJ, Smith DC. Advances in prostate cancer chemotherapy: A new era begins. CA Cancer J Clin 2005;55(5):300-18. Abstract

Ryan CJ, Eisenberger M. Chemotherapy for hormone-refractory prostate cancer: Now it’s a question of “when?”. J Clin Oncol 2005;23(32):8242-6. Abstract

Tannock IF et al; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12. Abstract

Walsh PC. Radical prostatectomy versus watchful waiting in early prostate cancer. J Urol 2005;174(4 Pt 1):1291-2. No abstract available

Home